

# Cameroon Impact, Mid-Year 2012

Mid-year 2012, PSI has averted an estimated 86,503 DALYs in Cameroon. This is 22% of their own program target for 2012.

## CAMEROON PROGRAM PERFORMANCE

	2012 YTD	% Change from 2011 YTD	% 2012 Program Target	2012 Program Target
<b>SCALE</b>				
■ DALYs Averted	86,503	-4%	22%	397,609
■ Couple Years of Protection (CYP)*	140,586	-3%	38%	365,642
■ Burden Averted	1.0%			

### RELEVANCE


	VALUE		VALUE
■ Health Relevance	46%	■ 2011 Net Cost per DALY	\$24
■ Family Planning Method Mix**	5 with 2 LTM	■ 2011 Net Cost per CYP	\$19

\* CYPs based on new USAID conversion factors, except IUDs

\*\* Target is 4 or more FP modern methods with at least one long-term method

## CAMEROON

### Map



## CAMEROON HEALTH AREA PERFORMANCE

Current PSI Product & Service Health Areas	2012 YTD			% of Country Total Burden
	DALYs Averted	% Change from 2011 YTD	Burden Averted	
HIV & STD	39,597	-31%	3.3%	15.2%
Reproductive Health	26,164	-6%	2.0%	12.5%
Malaria	15,933	299%	1.9%	10.7%
Diarrheal Diseases	4,810	240%	0.7%	8.1%
Potential 14% increase in relevance with expansion of existing PSI products and services				% of Country Total Burden
Tuberculosis				1.2%
Nutritional Deficiencies				2.4%
Respiratory Infections				10.7%


## CAMEROON

### Platform Profile

Population	19,598,889
Population under 5	3,054,802
Women aged 15-49	4,763,850
# Platform interventions	13
# Family planning interventions	5 with 2 LTM
Contraceptive prevalence	12.0% (2006)

\* Population data from UN Population Division, 2010 revision

## PSI RELEVANCE: 2012 DALYs AVERTED YTD COMPARED TO BURDEN OF DISEASE (WHO 2004)\*



- **Innovation in Other Health Areas:** Burden from non-communicable diseases and injuries
- **Innovation in Communicable Diseases:** Additional communicable burden not addressed by PSI
- **Expansion:** % disease burden targeted by existing PSI products and services not in use by country platform
- **Health Relevance:** % disease burden targeted by current country platform products and services
- **Burden Averted:** % DALYs averted by PSI in 2012 YTD as proportion of WHO (2004) Burden of Disease DALYs

- In 2012 YTD, 0.5% of global DALYs were averted by PSI.

- In Cameroon, 1.0% of DALYs were averted by PSI in 2012 YTD.

Note: Updated WHO Global Burden of Disease estimates produced by IHME are anticipated late 2012


## CAMEROON PRODUCTS & SERVICES DALYS AVERTED (from highest to lowest DALYs averted)

Products	2012 YTD DALYs**	% Change from 2011 YTD	2012 YTD # Distributed	2012 Targeted Distribution	% of 2012 Target	2011 unit COGS	2012 YTD CYPs
Condom	56,081	-1%	10,539,289	28,000,000	38%	\$0.04	87,827
Malaria PPT (ACT)	15,916	415%	281,666	140,000	201%	\$0.59	
Diarrhea Treatment Kit	4,521	359%	115,718	50,000	231%	\$0.03	
IUD Insertion	3,964	2416%	6,341	11,760	54%	\$0.46	22,194
IUD Distribution	2,548	370%	10,676	14,550	73%	\$0.46	15,176
Implant 5 Insertion	1,774	350%	3,569	6,433	55%	\$21.83	13,562
Female Condom	908	-97%	178,490	700,000	25%	\$0.35	1,487
Injectable 3	824	221%	17,675	10,000	177%	\$1.33	4,419
Safe Water Solution	289	-33%	16,361	50,000	33%	\$0.45	
VCT	163	204%	5,241	6,800	77%	\$0.95	
LLINs	17	-98%	60	740,000	0%	\$6.18	
OCs	2	*	150	30,000	1%	\$0.21	10
Misoprostol	0	*	-	60,000	0%		
ORS	0	*	-	50,000	0%		
Implant 5 Distribution	-503	-251%	2,487	1,433	174%	\$21.83	(4,089)
Water Treatment Tablets				100,000	0%		
<b>Total</b>	<b>86,503</b>	<b>-4%</b>					<b>140,586</b>

\* Product was not distributed in YTD 2011

\*\*DALYs averted and CYPs provided may be negative for products distributed in cases where PSI has distributed and inserted the same product. This is because DALYs averted and CYPs are calculated separately for products that are distributed and inserted; to avoid double counting, insertion DALYs and CYPs are subtracted from distribution.

## PROGRESS TOWARD CAMEROON 2012 PROGRAM DISTRIBUTION TARGETS (% of 2012 Target)



\* Targets are set by # of products distributed.